Paratek Pharmaceuticals, Inc. (PRTK)
(Delayed Data from NSDQ)
$5.36 USD
+0.04 (0.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.35 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.36 USD
+0.04 (0.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.35 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 19.35% and 15.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
argenex SE (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 7.89% and 1.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 3.39% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -9.09% and 59.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
Paratek Pharmaceuticals (PRTK) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -31.03% and -3.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -77.27% and -49.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?
by Zacks Equity Research
Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 24.59% and 14.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Paratek Pharmaceuticals (PRTK) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Paratek Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?